TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06830863: A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Sponsor: Azitra Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$931,260

Rescue Site Savings

+$620,840

Unlock Full NCT06830863 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06830863 Rescue Dossier →